Julio Flamini
Neurology · Atlanta, GANPI 1437225737
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $301,079 of the $500,542 with a category attached, or 60.2%. 60 manufacturers reported payments, led by UCB, Inc. at 35.4% of the total. Among neurology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,923 payments — averaging $260.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$177K
- Greenwich Biosciences, Inc.$52K
- Neurelis, Inc.$47K
- Jazz Pharmaceuticals Inc.$46K
- Eisai Inc.$45K
- Biocodex, Inc.$23K
- plus $111K from 54 others
Across 163 payments — averaging $6968.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$536K
- SK Life Science, Inc.$297K
- Aquestive Therapeutics, Inc.$87K
- Supernus Pharmaceuticals, Inc.$67K
- Zogenix Inc.$62K
- Purdue Pharma L.p.$25K
- plus $61K from 4 others
What the payments were for
- Consulting fees$109,57622%
- Speaking & faculty fees$301,07960%
- Travel & lodging$45,7779%
- Food & beverage$44,0689%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$145,096
- Epidiolex$90,441
- VALTOCO$44,631
- Fycompa$39,384
- DIACOMIT$22,848
- SYMPAZAN$20,516
- APTIOM$14,192
- Briviact$12,330
- ZTALMY$9,917
- Banzel$9,726
- VNS Therapy$4,464
- Vimpat$2,882
- Cenobamate$1,900
- XCOPRI$1,900
- Nayzilam$1,800
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$1,100
- OXTELLAR XR$613
- DYSPORT$267
- AJOVY$251
- QELBREE$240
How this compares
$500,542 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 13 | $255,585 |
| BriviactBrivaracetam | 12 | $23,458 |
| XcopriCenobamate | 14 | $19,055 |
| OnfiClobazam | 11 | $15,474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact | $177,352 | $279,04325 claims |
| SK Life Science, Inc.Xcopri | $4,934 | $19,05514 claims |
| Lundbeck LLCOnfi | $533 | $15,47411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.
Other neurology in Atlanta
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- Frank BerensonAtlanta$527K
- Douglas StuartAtlanta$493K
- Robert GilbertAtlanta$412K
- Lawrence SeidenAtlanta$272K
- Jacqueline RosenthalAtlanta$241K
- Ben ThrowerAtlanta$203K
- Jaime Hatcher MartinAtlanta$165K
- Andrei SerbanescuAtlanta$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.